<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067153</url>
  </required_header>
  <id_info>
    <org_study_id>2021-001335-24</org_study_id>
    <nct_id>NCT05067153</nct_id>
  </id_info>
  <brief_title>Thromboprophylaxis in Oesophageal Cancer Patients</brief_title>
  <acronym>TOP-RCT</acronym>
  <official_title>Thromboprophylaxis in Oesophageal Cancer Patients - A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the efficacy and safety of prolonged&#xD;
      thromboprophylactic treatment with Fragmin® in oesophageal cancer patients undergoing&#xD;
      intended curative surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses&#xD;
&#xD;
        1. The intervention group of oesophageal cancer patients, who receive prolonged&#xD;
           thromboprophylaxis with Fragmin® has a lower VTE risk, expressed by a lower prothrombin&#xD;
           fragment F1+2, 30 days after surgery than the control group, who receive Fragmin® for 10&#xD;
           days.&#xD;
&#xD;
        2. The intervention group does not demonstrate an increased bleeding tendency compared with&#xD;
           the control group.&#xD;
&#xD;
      Primary endpoint The primary endpoint is the difference in prothrombin fragment F1+2 30 days&#xD;
      after surgery between the intervention and the control group.&#xD;
&#xD;
      Secondary and safety endpoints The secondary endpoints are incidence of bleeding, VTE and&#xD;
      mortality 30 days and one year after surgery.&#xD;
&#xD;
      Study design&#xD;
&#xD;
      The study is comprised of three specific objectives, presented in three work packages (WP):&#xD;
&#xD;
        -  WP1: Randomization of 100 oesophageal cancer patients undergoing intended curative&#xD;
           surgery to either a 10 or 30-day prophylactic LMWH-regime.&#xD;
&#xD;
        -  WP2: Investigation of the coagulation in the WP1 population. The aim is to substantially&#xD;
           improve understanding of the coagulation pathophysiology and the mechanisms behind the&#xD;
           increased thromboembolic risk in oesophageal cancer patients.&#xD;
&#xD;
        -  WP3: The lectin pathway complement proteins are suspected to play a role in the&#xD;
           increased risk of thrombosis in cancer. We aim to examine this further by measuring&#xD;
           complement protein levels in the WP1 population and investigate if there is a&#xD;
           correlation between complement levels and changes in the coagulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled trial with one intervention group and one control group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking due to ethical considerations. Primary outcome is biochemical.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prothrombin fragment F1+2</measure>
    <time_frame>30 days after surgery.</time_frame>
    <description>Difference in prothrombin fragment F1+2 between the intervention and the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days after surgery.</time_frame>
    <description>Incidence of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolic events</measure>
    <time_frame>30 days and one year after surgery</time_frame>
    <description>Incidence of venous thromboembolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days and one year after surgery</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Thrombosis</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group (n=50, anticipated) receives 30 days postoperative treatment with 5000 IE LMWH daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group (n=50, anticipated) receives standard 10 days postoperative treatment with 5000 IE LMWH daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fragmin 5000 UNT in 0.2 ML Prefilled Syringe</intervention_name>
    <description>30 days postoperative prophylactic treatment.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Low Molecular Weight Heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cancer located in oesophagus and/or cardia.&#xD;
&#xD;
          2. Candidate for intended curative surgery.&#xD;
&#xD;
          3. Age &gt; 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known inherited bleeding disorder.&#xD;
&#xD;
          2. Unable to provide informed consent.&#xD;
&#xD;
          3. Arterial or venous thromboembolic events within the last three months.&#xD;
&#xD;
          4. On-going anticoagulant treatment (Vitamin K antagonists or direct oral&#xD;
             anticoagulants).&#xD;
&#xD;
          5. Pregnant or has given birth within the last three months.&#xD;
&#xD;
          6. Known allergy to the trial drug Dalteparin (Fragmin®).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Mette Hvas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Mette Hvas, MD</last_name>
    <phone>004578455252</phone>
    <email>annehvas@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tua Gyldenholm, MD</last_name>
    <phone>004525136781</phone>
    <email>tuagyl@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thrombosis and Haemostasis Research Unit, Department for Clinical Biochemistry, Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Mette Hvas, MD, Ph.D.</last_name>
      <phone>+45 2334 8252</phone>
      <email>annehvas@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Anne-Mette Hvas, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tua Gyldenholm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Decker Christensen, MD, PhD, DMSci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niels Katballe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel W Kjær, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

